Sunovion signs deal with Portugese company to distribute Parkinson's drug
Photo | Grant Welker
Sunovion's Marlborough headquarters
Marlborough company Sunovion Pharmaceuticals announced on Thursday it granted exclusive commercial license rights in Europe to Portugese company Bial for Sunovion's KYNMOBI, an under-the-tongue drug treating OFF episodes in patients with Parkinson’s disease.
Under the agreement, Bial will undertake the marketing applications and authorization procedures in Europe in order to distribute and commercialize the drug in the European Union, the European Economic Area, and the United Kingdom, according to the release.
Sunovion will continue to hold the exclusive commercial rights to KYNMOBI in North America and other regions including the EU, EEA, and United Kingdom.
Bial will provide payment to Sunovion for the licensing of KYNMOBI, although the exact amount was not disclosed.
OFF episodes occur when people suffering from Parkinson's disease cannot perform everyday activities and are characterized, in part, by tremor, stiffness, slowed movement or other symptoms. An estimated 10 million people will be living with Parkinson's disease by 2020, according to Sunovion.
WBJ Web Partners
Most Recent
Most Recent
0 Comments